Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Entera Bio Ltd
ENTX | US
1.25
USD-0.02
-1.57%
ENTX | US
Loading StockChartView...
About Entera Bio Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
1.25
Open
1.25
High
1.26
Low
1.18
Entera Bio Ltd. a clinical-stage biopharmaceutical company focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612 which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2 which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem Israel.
View LessENTX | US
Risk
84.8
Sharpe
-0.44
Luna's Score
36/100
Recommendation
Sell
Luna says (ENTX | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
73.5%1 month
84.8%3 months
98.0%6 months
100.8%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
7.88
Debt to equity
0.04
Debt to assets
0.03
Ent. to EBITDA
-1.52
Ent. to rev.
1.03K
PEG
-
Other Fundamentals
EBITDA
-8.53M
MarketCap
45.41M
MarketCap(USD)
45.41M
Div. yield
-
Op. margin
-3.80K
Erngs. growth
-
Rev. growth
-91.50
Ret. on equity
-101.84
Short ratio
0.97
Short perc.
0.15
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.19
Range1M
0.28
Range3M
0.66
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.30
Price X volume
165.06K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.52 | 0.53 | Cheaper |
| Ent. to Revenue | 1,025.94 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 7.88 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 98.00 | 72.80 | Riskier |
| Debt to Equity | 0.04 | -1.23 | Expensive |
| Debt to Assets | 0.03 | 0.25 | Cheaper |
| Market Cap | 45.41M | 3.66B | Emerging |
